Panel Discussion: Unravelling the Rationale Behind Combination Therapy & Critical Design & Development Considerations for Emerging Therapeutic Candidates

Time: 3:15 pm
day: Day Two


• Exploring the current limitations of single agent therapeutics and the scientific rationale behind targeting multiple pathways and processes for enhanced efficacy in halting fibrosis

• Critical considerations into clinical trial design in combination therapy including patient population selection based on specific signatures predicting a better response to combination

• Defining appropriate endpoints for combination therapy trials beyond traditional single-agent measures moving from slowing the rate of decline to faster and more apparent measures of improvement